Roadshow
PCR-CE Multiplex Molecular Diagnostics Platform
Our company has developed a PCR-CE-based multiplex molecular diagnostic platform featuring patented primer design technology. The platform enables integrated analysis of repeat sequences, copy number variation (CNV), and highly homologous genes in a single workflow. It has been applied to genetic disease testing, including FMR1, SMN1/SMN2, DMD, and thalassemia.
Compared with conventional workflows that require multiple methods such as MLPA, Sanger sequencing, or NGS and typically take three days to several weeks, our platform integrates complex testing into a standardized single-tube, multi-locus assay that can be completed within 2–3 hours. Its key advantages include stable amplification of high-GC repeat regions, precise differentiation of SMN1 and SMN2, single-tube CNV analysis of all 79 DMD exons, and detection of unknown deletions and HBA gene duplications in thalassemia, offering a rapid, accurate, simplified, and clinically scalable solution.
- Established 2018
- Company Origin Biotechnology., Ltd.
- Telephone +886 02-3393-1118#12
- Email yuwei@oribio.com.tw
- Address 5F.-1, No. 12, Linsen S. Rd., Zhongzheng Dist., Taipei, Taiwan
Origin is an innovative biotechnology company based on autonomous research and development to the field of molecular diagnostics. Our business strategy aims to develop rapid, accurate IVD kit to fulfill unresolved clinical demands. Our mission focus on prevention, screening, and diagnose of gynecological, pediatric, and genetic disease. Origin have recently made significant breakthroughs in developing a comprehensive panel for genetic disease testing and a full-scope fragment analysis solution, offering an advanced alternative to the current CNV gold standard. Our product portfolio demonstrates outstanding performance in FXS, SMA, and Thalassemia testing in both specifications and coverage. Moreover, we offer the world’s first and only IVD assay for Kawasaki Disease, addressing an urgent unmet need in pediatric diagnostics.